ArticleCurrent microbiology2021
Antifungal Properties, Abiotic Stress Resistance, and Biocontrol Ability of Bacillus mojavensis PS17.
Article in Current microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 43 citations in OpenAlex.
- In vitro and in silico analysis of the fungicidal potential of secondary metabolites from a bacterial endophyte against Botrytis cinerea.BMC biotechnology · 2026Article
- Harnessing Seed Endophytic Microbiomes: A Hidden Treasure for Enhancing Sustainable Agriculture.Plants (Basel, Switzerland) · 2025Review
- Evaluation of Bacillus isolates as a biological control agents against soilborne phytopathogenic fungi.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Characterization of EndophyticJournal of microbiology and biotechnology · 2024Article
- Enhancing drought stress tolerance and growth promotion in chiltepin pepper (Capsicum annuum var. glabriusculum) through native Bacillus spp.Scientific reports · 2024Article
- Plant Growth Promotion and Plant Disease Suppression Induced byPlants (Basel, Switzerland) · 2024Article
- Identification and Aggressiveness ofJournal of fungi (Basel, Switzerland) · 2024Article
- Novel EndophyticToxins · 2023Article
- Genomic Insights into the Microbial AgentMicroorganisms · 2023Article
- Plant growth-promoting and heavy metal-resistant Priestia and Bacillus strains associated with pioneer plants from mine tailings.Archives of microbiology · 2023Article
- Antifungal mechanisms of the antagonistic bacteriumFrontiers in microbiology · 2023Article
- Article
- Biosynthetic Mechanisms of Secondary Metabolites Promoted by the Interaction Between Endophytes and Plant Hosts.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-protecting Bacillus sp. strains used as biocontrol agents frequently produce metabolites inhibiting phytopathogenic fungi. Recently, the search for a novel biocontrol agent with a wide spectrum of disease control drew attention to Bacillus subtilis and their related species, including Bacillus mojavensis. In this study, we determined the antifungal properties of the endophytic B. mojavensis PS17 isolated from wheat seeds. Metabolites produced by B. mojavensis PS-17 inhibit the growth of Fusarium graminearum, Fusarium oxysporum, Fusarium chlamydosporum, Ascochyta pisi, Alternaria alternate, Sclerotinia sclerotiorum, Verticillium dahliaee, and Epicoccum nigrum strains. B. mojavensis strain PS17 produces several hydrolytic enzymes, such as chitinase, β-glucanase, cellulase, lipase, and protease. Additionally, strain B. mojavensis PS17 demonstrates drought tolerance under osmotic pressure of -2.2 MPa and a moderate halotolerance in 5% (w/v) of NaCl. B. mojavensis PS17 on tomato seedlings was able to reduce lesions of Forl ZUM2407 by 48.11% ± 1.07, showing the potentials of B. mojavensis PS17 to be adapted as a biocontrol agent for agricultural use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.